Drug intelligence / Profile preview

R&D112

Development stage: Unknown
Lead developer: Bostal Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

R&D112 is a long-acting injectable (LAI) formulation of an antipsychotic medication being developed by Bostal Drug Delivery for the treatment of schizophrenia. Utilizing the 505(b)(2) regulatory pathway, the drug is designed to provide a sustained release of the active ingredient over a three-month period (3M). This formulation aims to improve patient compliance and therapeutic outcomes by reducing the frequency of administration compared to daily oral medications or shorter-acting injectables. As of 2024, R&D112 is in the early stages of development, with Phase 1 clinical trials anticipated to begin in 2027.

Beyond the preview

Go deeper on R&D112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R&D112.

Explore the full profile